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hospital in Austria for the last two months of life of cancer
patients. METHODS:Two groups of cancer patients, who had at
least one stay in the inpatient palliative care unit, were formed
retrospectively. All patients died in 2005 or 2006. Patients in the
control group “no home care support team—NHCST” only got
inpatient care. Patients in the intervention group “home care
support teams—HCST” got additional home care support.
Patients of NHCST and HCST were matched by age, sex and
main diagnosis to ensure that patients in both groups were com-
parable (N = 60 for each group). Only public health care expen-
ditures were considered. Data comprised of the Minimum Basic
Data Set from all public hospitals in Styria and the follow-up
costs dataset from the largest compulsory health insurance insti-
tution of Styria. Health care expenditures were allocated to costs
for inpatient care, costs for outpatient care (general medicine,
specialized medicine, drugs, assistive technology, costs of trans-
port), and costs of home care support teams. Finally, health care
expenditures of the last two months of life were compared for
both groups. RESULTS: Mean costs for inpatient care of
NHCST/HCST are €7502/€5843 (€1659/22.1% /p = 0.035).
Mean costs for outpatient care of NHCST/HCST are €1106/
€1391 (€ + 285 / + 25.8% / p = 0.063). The mean costs for home
care support teams are €1290 for HCST group. Total health care
costs are almost the same for both groups (HCST: €8524 vs.
NHCST: €8608 /€ + 84 / + 1% / p = 0.988). CONCLUSIONS:
HCST shows tendency of being self-ﬁnancing due to savings of
inpatient care for the last two months of life of cancer patients.
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OBJECTIVES: Opioids comprise the main option in the man-
agement of moderate-to-severe cancer pain. Different opioids are
used in rotation to eliminate tolerance and opioid side effects that
limit increasing dose. Since there are only two non-parenteral
opioids—morphine and fentanyl—in Turkey, pain control with
rotation might not be successfully done and invasive treatment
modalities are to be selected much earlier than optimal. The aim
of the study is to evaluate the contribution of the addition of a
new long-acting oral opioid (OROS hydromorphone) into the
current opioid market, with regard to the cost of treatment in
moderate-to-severe cancer pain. METHODS: Model: Decision
tree modeling to compare the current two-opioid-market with
the hypothetical three-opioid-market, is used in the calculation of
costs. Patients are treated with rotation of two and three opioids
in the current and hypothetical market respectively. Time horizon
is eight weeks. The study has been performed from the health
care payer perspective. Data sources: The clinical data are
acquired from the literature. Prices of medications, discount
rates, other costs related to the treatment are obtained from
Ministry of Health Drug Price List, Price List of Social Security
Institution Health Implementation Guideline Appendix 2/D and
8, respectively. Analysis: Direct medical costs that are considered
are the costs of opioids, invasive treatment modalities, side
effects, physician visits and hospitalization. Because time horizon
is shorter than 1 year, costs are not discounted. The results are
presented as total costs of alternatives. RESULTS: Costs of
treatment are calculated as €1528/patient for the current two-
opioid-market and €1070€/patient for hypothetical three-opioid-
market. The amount of saving is €458/patient. CONCLUSIONS:
Inclusion of OROS hydromorphine into the Turkish market will
both increase the chance of patients be treated with non-
parenteral opioids without need to non-invasive methods and
also provide saving in the total medical costs of treatment.
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OBJECTIVES: Particle therapy (PT) with protons or carbon-
ions appears more effective in cancer treatment than conven-
tional treatment with photons. The investment costs are
however much higher. For a reliable estimate of the cost-
effectiveness of particle therapy an objective cost estimate is
crucial. Therefore, an extensive cost analysis was performed for
each facility. METHODS: An analytical framework with all rel-
evant parameters based on literature review and expert opinion
was built in Excel. Costs were calculated for: (A) combined
carbon-ion and proton facility (B) proton-facility, (C) photon-
facility. The total costs per year were calculated as the sum of the
capital costs divided by the life cycle of the facility (30 years) and
the running costs per year. The cost per fraction was calculated
as total costs per year divided by number of fractions per year.
The number of fractions per year was calculated in an opera-
tional model. RESULTS: The capital costs per facility are: (A)
€138.6 m, (B) €94.9 m, (C) €23,4 m. The annual running costs
are: (A) €21 m, (B) €14.2 m (C) 6,9 m. The costs per fraction per
facility are: (A) €787, (B) €516, (C) €187. The cost ratio is 4.2
for the combined-facility vs photon-facility and 2.8 for the
proton-facility vs photon-facility. The incremental costs are €600
and €329 per fraction, respectively. The costs per fraction for (C)
increased to 543€ when special treatment category tumors only
were included. A 20% variation in the annual number of frac-
tions, capital costs and running costs, resulted in changes in the
cost per fraction from -17% to +25%. The number of fractions
caused the biggest change, the capital costs the smallest. CON-
CLUSIONS: A combined carbon-ion/proton facility is the most
costly facility, followed by a proton facility. The outcomes are
most sensitive for the patient throughput, patient mix, and
average time per fraction.
PCN67
COST UTILITY ANALYSIS OF ALEMTUZUMAB COMPAREDTO
CHLORAMBUCIL IN UNTREATED PATIENTS WITH HIGH-RISK
(17P-) CHRONIC LYMPHOCYTIC LEUKEMIA INTHE UNITED
KINGDOM
Lloyd AC1,Valderrama A2, Ferguson J3, Gilmour L3, Ravndal F1
1IMS, London, UK, 2Bayer Healthcare Pharmaceuticals Inc, Pine Brook,
NJ, USA, 3Bayer Healthcare Pharmaceuticals Inc, Newbury, Berkshire,
UK
OBJECTIVES: To compare costs and outcomes of alemtuzumab
and chlorambucil as ﬁrst line treatment for patients with high-risk
(17p-) chronic lymphocytic leukemia (CLL) in the UK.
METHODS: A lifetime Markov model was developed. Patients
were modeled receiving treatment and moving through post-
treatment response and progressive disease. Three possible lines of
chemotherapy were considered, followed by ﬁnal disease progres-
sion and death. Patients had CLL, were chemotherapy naïve and
exhibited deletion of the chromosome 17p, a defect associated
with poor prognosis and failure to respond to other CLL thera-
pies. Response rate and duration at ﬁrst line were taken from a
recent randomized study, the CAM307 trial, for subsequent lines
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of therapy. A review of clinical literature was conducted. Utility
was estimated from a survey of the general public using a time-
trade-offmethodology. Costswere calculated from the perspective
of the UK National Health Service. Future costs and beneﬁts were
discounted at 3.5%. RESULTS: When overall survival (OS) was
assumed to be equal, treatment with alemtuzumab instead of
chlorambucil increased lifetime cost per patient from £10,957 to
£17,938 and increased QALYs per patient from 1.59 to 1.96 at a
cost of £18,788 per QALY gained. When OS was allowed to vary
to reﬂect differences in progression free survival the cost perQALY
fell to £14,604. Findings were most sensitive to the cost of the
interventions, response rate and duration at ﬁrst line. CONCLU-
SIONS:This study found that in theUK, the cost perQALYgained
with ﬁrst-line alemtuzumab therapy over chlorambucil is £18,788
in high-risk (17p-) CLL patients.
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OBJECTIVES: To conduct a cost utility analysis of docetaxel-
doxorubicin (AT) vs standard doxorubicin-cyclophosphamide
(AC) chemotherapy as neoadjuvant therapy for patients with
locally advanced breast cancer in Poland. METHODS: We devel-
oped a cost-utility Markov model from a public payers’ perspec-
tive (National Health Fund), using clinical data from published
sources, Polish cost data, and a lifetime horizon.RESULTS: Based
on a systematic review, only one randomized clinical trial
was included in the comparison: AT (docetaxel 75 mg/m2 +
doxorubicin 50 mg/m2, every 3weeks,mean number of cycles 5.5)
vs AC (doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2,
every 3 weeks, mean number of cycles 5.5). Average costs of the
treatment for locally advanced breast cancer (including neoadju-
vant chemotherapy, treatment of serious adverse events, surgery,
additional post-operative therapy, health state monitoring, local
and distant relapse treatment and palliative care) were 53,677
PLN for AT and 33,716 PLN for AC. Treatment effects (per
patient) were 8,258 QALY and 9,081 LYG for AT and 7,191
QALYand 8, 075LYG forAC. ICER for theAT vsAC comparison
were 18,729 PLN/QALY and 19,842 PLN/LYG. The ICER values
were below the acceptable threshold for very cost-effective treat-
ment in Poland (27 000 PLN). CONCLUSIONS: The docetaxel
regimen is more effective and more expensive in the neoadjuvant
treatment of patients with locally advanced breast cancer com-
pared with AC chemotherapy. ICERs are below the acceptable
threshold, therefore the docetaxel therapy can be considered a
cost-effective treatment for locally advanced BC in Poland.
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OBJECTIVES: Rituximab has recently received European
approval for its use in combination with any chemotherapy. The
aim of this study is to evaluate the cost-effectiveness of rituximab
added to the most commonly used chemotherapy regimens, per-
formed from the Spanish National Health System perspective.
METHODS: We developed a Markov model based on 3 random-
ized controlled clinical trials comparing the addition of ritux-
imab to chemotherapy regimens of CVP; MCP or CHOP vs
chemotherapy alone, in patients with advanced follicular lym-
phoma. Progression-free survival (PFS) and overall survival were
the endpoints evaluated in these trials. Rates of disease progres-
sion were derived from the PFS Kaplan-Meier curves, mortality
rates were obtained from the Scotland-Newcastle Lymphoma
Group database and Spanish age-speciﬁc mortality tables;
resource consumption data was based on a local expert panel
questionnaire and patient utilities to account for quality of life
were applied to the PFS and progressed health states. Medication
and supportive care costs, and quality-adjusted life years
(QALYs) were estimated over 10 years and discounted at 3.5%.
Univariate and probabilistic sensitivity analysis were performed.
RESULTS: The addition of rituximab to chemotherapy increased
QALYs by 0.795, 1.129 and 0.971 years for CVP, MCP and
CHOP, respectively, compared to chemotherapy alone. The
incremental cost per QALY gained was €10,190, €6,092 and
€7,855, for CVP, MCP and CHOP, respectively. The incremental
cost per life year gained was €10,168, €6,348 and €8,190, for
CVP, MCP and CHOP, respectively. Sensitivity analyses indicated
the results were robust, and most sensitive to the duration of
treatment effect and time horizon. CONCLUSIONS: The addi-
tion of rituximab to any of the chemotherapy regimens evalu-
ated, was estimated to increase quality-adjusted life expectancy,
and be a highly cost-effective treatment option for patients with
advanced follicular lymphoma.
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OBJECTIVES: To assess the cost-effectiveness of treating, in an
observational setting, ﬁrst-line Chronic Lymphocytic Leukaemia
(CLL) patients in the USA with Rituximab, Fludarabine and
Cyclophosphamide (R-FC) versus FC alone (Tam et al., 2008).
METHODS: A 3-state semi-Markov model was developed with
rates of disease progression obtained from the Progression Free
Survival curves (R-FC n = 300; FC n = 108, 6 year median
follow-up) using the best ﬁt (Weibull) function, and rates of
death in the PFS and progressed states based on background
mortality and observed CLL mortalities respectively. Published
utility values of 0.8 and 0.6 were applied to PFS and progressed
health states and no treatment beneﬁt was assumed beyond the
observational period. Costs were estimated using Medicare reim-
bursed rates, MS-DRGs for CLL and published drug prices, and
include the cost of administration and adverse events. Costs (in
USD) and quality-adjusted life-years (QALYs) were estimated
over a lifetime horizon (30 years) and discounted at 3% per
annum. RESULTS: Average lifetime health service costs per
patient were $51,694, and $29,192 for R-FC and FC respec-
tively. Life expectancy was estimated as 9.9 years for R-FC and
7.7 years for FC. Average QALYs for R-FC and FC were 7.3 and
5.5 years respectively. The incremental cost-effectiveness ratio for
R-FC compared to FC was $10,291 per life year gained and
$12,382 per QALY gained. The modeled results were robust to
sensitivity analyses assessing the uncertainty about costs and
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